Retatrutide appears to be a new treatment in the fight against obesity. This groundbreaking drug, categorized as a dual GLP-1 and GIP receptor agonist, shows promising results in investigations. By stimulating these receptors, Retatrutide reduces hunger pangs, {promotesinsulin secretion, and ultimately contributes to significant reduction in body m